The products, which will be available in doses of 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg and 10 mg/320 mg, are generics of Novartis’ high blood pressure treatment Exforge (amlodipine/valsartan).

Amlodipine/valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker and valsartan, an angiotensin II receptor blocker.

Exforge is indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. High blood pressure (hypertension) is a chronic condition often without symptoms that is linked to serious health issues such as heart disease and stroke, if not detected early and treated appropriately.

Amlodipine and valsartan tablets had approximately US$415.3 million in the US for the 12 months ending 31 December 2014, according to IMS Health.

Related articles
Generic valsartan approved in US

Taiwan TWi gains FDA approval for generic nifedipine

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.